Patents Issued in August 21, 2018
  • Patent number: 10052270
    Abstract: Described herein are oral care compositions comprising (i) a peroxide whitening agent comprising a whitening complex of crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, (ii) sodium acid pyrophosphate (Na2H2P2O7) in an amount of from 0.05 wt % to 5 wt % based on the weight of the composition, and (iii) less than 3 wt % water based on the weight of the composition.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: August 21, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Michael Prencipe, Prakasarao Mandadi, Olivier Garot
  • Patent number: 10052271
    Abstract: A solid stick antiperspirant composition is provided. The antiperspirant composition includes aluminum zirconium tetrachlorohydrex glycine having a concentration from about 10% to about 35% by weight of the composition, an anhydrous liquid carrier, one or more structurants having a concentration from about 15% to about 25% by weight of the composition, wherein the one or more structurants comprises one or more waxes and a non-ionic exthoxylated linear alcohol having a carbon chain length from about 20 to about 40. The solid stick antiperspirant composition is a single phase.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: August 21, 2018
    Assignee: The Procter & Gamble Company
    Inventors: David Arthur Sturgis, Phi Van Chu, Steven Michael Wujek, Sr.
  • Patent number: 10052272
    Abstract: The present invention relates to a composition comprising isosorbide monooleate, a first surfactant selected from the group consisting of an alkyl glycoside having a weight average of the number of C-atoms in the alkyl chain of more than 11, cocoamidopropyl betaine and mixtures thereof, a second surfactant which is an alkyl glycoside having a weight average of the number of C-atoms in the alkyl chain of less than 11 and water. Furthermore it relates to a process for making this composition and to a cosmetic formulation, comprising this composition.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: August 21, 2018
    Assignee: BASF SE
    Inventors: Claudia Stoer, Claus Nieendick, Markus Weissenegger, Daniela Prinz, Mirella Winzek, Jennifer Schoss, Markus Dierker, Norbert Boyxen, Ute Griesbach, Werner Seipel, Werner Mauer
  • Patent number: 10052273
    Abstract: The present invention relates to a method for dyeing keratinous fibers, in particular human keratinous fibers, such as the hair, in which the said fibers are treated starting from one or more cosmetic compositions comprising a) one or more ortho-diphenol(s), b) one or more inorganic titanium salt(s) or alkoxytitanium(s), c) one or more acid(s) and d) optionally one or more chemical oxidizing agent(s), such as hydrogen peroxide or one or more hydrogen peroxide generating system(s).
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: August 21, 2018
    Assignee: L'Oreal
    Inventors: Boris Lalleman, Alain LaGrange
  • Patent number: 10052274
    Abstract: Disclosed is a foam booster that is capable of producing or increasing the amount of foam in any given composition. The foam booster includes a saccharide blend having 30 wt. % to 50 wt. % of an aldohexose or mixture of aldohexoses, 20 wt. % to 55 wt. % of a ketohexose or mixture of ketohexoses; and 10 wt. % to 20 wt. % of a disaccharide or mixture of disaccharides.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 21, 2018
    Assignee: Coast Southwest Inc.
    Inventors: Shannon Smith Butz, Amit Patel
  • Patent number: 10052275
    Abstract: Disclosed is a self-reversible reverse latex including: a) 25-80% by mass of a cross-linked anionic polyelectrolyte (P), resulting from the polymerization, for 100 mole percent: i)—of a molar proportion ?30% and ?95% of monomeric units from at least one monomer including a free, partially- or totally-salified strong acid function; and ii)—of a molar proportion >0% and ?5% of at least one monomer with diethylenic or polyethylenic cross-linking; b) 0.5-10% by mass of a terpolymer of stearyl methacrylate, pentacosaethoxylated behenyl methacrylate and N,N-dimethylacrylamide, resulting from the polymerization, for 100 mole percent: of 80-95 mole percent of stearyl methacrylate, of 2.5-10 mole percent of N,N-dimethylacrylamide, and of 2.5-10 mole percent of pentacosaethoxylated behenyl methacrylate, c) 5-40% by mass of at least one oil, and d) 0.1-40% by mass of water; method of preparing same and use thereof as a thickener.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: August 21, 2018
    Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
    Inventors: Paul Mallo, Olivier Braun
  • Patent number: 10052276
    Abstract: A fragrance extending product containing a fragrance treatment complex is disclosed to extend the effective life of the fragrance carried by a fragrance-bearing product, such as perfume and cologne. The fragrance extending product is preferably a spray-on product that can be applied over the top of the fragrance-bearing product. The fragrance treatment complex resists the evaporation of the perfume oils from the fragrance-bearing product, as well as resists removal caused by abrasion and binding with water. The fragrance treatment complex formulation includes acrylates/octylacrylamide copolymer; Polyquaternium 11, a quaternized copolymer; guar hydroxypropyltrimonium chloride, a cationic polymer, and cocamidopropyl PG-dimonium chloride, a phospholipid. Tests have shown that the effective life of a fragrance-bearing product can be more than twelve hours with the application of the fragrance treatment complex over the fragrance-bearing product previously applied to a human body.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: August 21, 2018
    Assignee: HBWC Corporation
    Inventors: Paul F. Mazzotta, Josephine Sullivan
  • Patent number: 10052277
    Abstract: Compositions are provided that provide release of fragrance over an extended period of time. The compositions comprise a hydrophilically-modified cross-linked silicone elastomer and an acrylic rheology modifier.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 21, 2018
    Assignee: Avon Products, Inc.
    Inventors: Michael A. Lull, William E. McNamara, Glen T. Anderson
  • Patent number: 10052278
    Abstract: A method of treating a person's skin comprising topically applying to skin a composition that includes an effective amount of a hydrolyzed algae extract that includes an exopolysaccharide from Halymenia durvillei and an effective amount of an exopolysaccharide from Vibrio alginolyticus. Topical application of the composition can decrease skin permeability, increase filaggrin production, increase skin moisture, increase occludin production, and/or decrease TNF-? production.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 21, 2018
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Carle, Bob Foley, Julia Collier, Wanli Zhao, Geetha Kalahasti
  • Patent number: 10052280
    Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: August 21, 2018
    Assignee: Biogen Chesapeake LLC
    Inventor: Sven Martin Jacobson
  • Patent number: 10052281
    Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 21, 2018
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Koichi Kitamura, Maho Kondo, Kiyoshi Shimoyama, Toru Kurosawa
  • Patent number: 10052282
    Abstract: A pet hydration system comprising of specific ranges of vitamins and minerals conducive to a pet's health, with such nutrients placed into a liquid beverage and ultimately dispensed via a compartmentalized beverage dispenser. The compartmentalized beverage dispenser is formed such that separate liquids are measured out and dispensed to the pet in a manner that the pet receives the optimal amount of nutrition.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 21, 2018
    Inventor: Sydney Baskins
  • Patent number: 10052283
    Abstract: Disclosed is a composition for forming an injectable hydrogel. The composition includes 1% by weight or less of a graphene-based material and 5% by weight or more of a triblock copolymer. The triblock copolymer may be a copolymer represented by Formula 1: wherein n is an integer from 8 to 540, m is an integer from 16 to 70, and R is H or a vinylcarbonyl group (CH2?CHCO—). When R in Formula 1 is a vinylcarbonyl group, the triblock copolymer may be crosslinked through the vinylcarbonyl group to form a nanogel. The composition can be prepared by a simple mixing process. In addition, the composition is substantially free from in vitro and in vivo stability problems encountered with conventional hydrogel compositions. Furthermore, the composition has high biocompatibility as well as excellent mechanical properties such as high storage modulus.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: August 21, 2018
    Assignee: Gwangju Institute of Science and Technology
    Inventors: Giyoong Tae, Da-ae Won
  • Patent number: 10052284
    Abstract: The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 21, 2018
    Assignee: TRANSLATE BIO, INC.
    Inventors: Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
  • Patent number: 10052285
    Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: August 21, 2018
    Assignee: MannKind Corporation
    Inventors: Edwin Amoro, Karel Vanackere, Michael A. White
  • Patent number: 10052286
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 21, 2018
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 10052287
    Abstract: A delivery vehicle comprising a core (1) surrounded by a digestible polymer shell (4) having a melting and/or softening point above the body temperature of an animal or human, wherein said core comprises a lipid and/or lipophilic active ingredient (2) dispersed in a continuous polymer matrix (3). The delivery vehicle can be used to release lipid and/or lipophilic active ingredients, such as pharmaceuticals, nutraceuticals, supplements, traditional/herbal medicine, or combinations thereof, after a predetermined lag time following ingestion.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: August 21, 2018
    Assignee: Nestec S.A.
    Inventors: Timothy James Wooster, Laurence Donato-Capel, Anwesha Sarkar, Simone Acquistapace
  • Patent number: 10052288
    Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 21, 2018
    Assignee: DA VOLTERRA
    Inventors: Francois Lescure, Jean De Gunzburg
  • Patent number: 10052289
    Abstract: The present invention relates to a composition comprising at least one active ingredient with low aqueous solubility, said active ingredient being present therein in a form noncovalently associated with nanoparticles formed by at least one POM polymer of formula (I), and in which said active ingredient is present in a proportion of at least 5 ?mol/g of POM. It is also directed towards the use of such nanoparticles, noncovalently associated with an active ingredient, with a view to increasing the aqueous solubilization of said active ingredient.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 21, 2018
    Assignee: Flamel Ireland Limited
    Inventors: Rémi Meyrueix, Rafael Jorda, Gauthier Pouliquen, You-Ping Chan, Olivier Breyne
  • Patent number: 10052290
    Abstract: The present invention provides an enteric-coated hemoglobin multiparticulate comprising a core, a hemoglobin formulation coating, an inner or sub-coating, and an enteric coating. The present invention also provides a method of preparing said enteric-coated hemoglobin multiparticulate. The present invention further provides a method for treating various diseases caused by oxygen deficiency comprising administering to a subject said enteric-coated hemoglobin multiparticulate in order to orally deliver the encapsulated hemoglobin-based oxygen carriers to a specific target of said subject in a controlled release manner.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 21, 2018
    Assignee: Billion King International Ltd.
    Inventors: Bing Lou Wong, Sui Yi Kwok
  • Patent number: 10052291
    Abstract: The present invention relates to electrospun fibers comprising i) a hydrophilic polymer that is soluble in a first solvent, ii) a bioadhesive substance that is slightly soluble in said first solvent, iii) optionally, a drug substance.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: August 21, 2018
    Assignee: DERMTREAT APS
    Inventors: Jens Hansen, Lars Hellerung Christiansen
  • Patent number: 10052292
    Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: August 21, 2018
    Assignee: PURINA ANIMAL NUTRITION LLC
    Inventors: Bill L. Miller, Jill A. Davidson, Cindie M. Luhman
  • Patent number: 10052293
    Abstract: A Curcumin infused milk beverage composition comprising 0.05% to 0.15% alkalized Curcumin, standardized milk with fat, sugar and stabilizing agents, wherein the pH of resultant composition is maintained at 6.8.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 21, 2018
    Inventor: Srikumar Misra
  • Patent number: 10052294
    Abstract: Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating rosacea comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 21, 2018
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Unni Santhosh, Annadurai Marimuthu Senthilkumar, Bodireddy Mohan Reddy, Rajendran Kamala, Mahender Rao Siripragada
  • Patent number: 10052295
    Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 21, 2018
    Inventor: William A. Shaver
  • Patent number: 10052296
    Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 21, 2018
    Assignee: NEVAKAR INC.
    Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
  • Patent number: 10052297
    Abstract: The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: August 21, 2018
    Assignee: PIERRE FABRE DERMO-COSMETIQUE
    Inventors: Corinne Dechelette, Nathalie Castex Rizzi, Laetitia Bonzom
  • Patent number: 10052298
    Abstract: The invention provides a method of increasing blood flow in a subject in need of increased blood flow by administering citrulline or a salt thereof and arginine or a salt thereof to the subject.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 21, 2018
    Assignees: Kyowa Hakko Bio Co., Ltd., National University Corporation Nagoya University
    Inventors: Masayuki Ochiai, Koji Morishita, Toshio Hayashi
  • Patent number: 10052299
    Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 21, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10052300
    Abstract: The present disclosure relates to methods and compositions for suppressing the growth of fungus on selected areas of the skin. A composition for suppressing deep seated fungal growth comprising conjugated linoleic acid, Punicic acid, or combination thereof, and niacinamide and L-aspartic acid is provided herein. Methods of making and using the composition are also presently provided.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: August 21, 2018
    Inventor: David Changaris
  • Patent number: 10052301
    Abstract: The present invention provides a method for treating a cancer in a subject involving administering to the subject a compound of formula (II) or (II?): wherein R1, R2, R3, R4, R5, R6 and R7 are independently H, OH, alkoxy or alkylcarbonyloxy, or a pharmaceutically acceptable salt thereof. Also provided is a compound of formula (II) or (II)?, wherein R1 and R2 are independently OH, alkoxy or alkylcarbonyloxy, R3 and R4 are independently H, OH, alkoxy or alkylcarbonyloxy, R6 is H, alkoxy or alkylcarbonyloxy, R5 is H, OH or alkylcarbonyloxy, R6 is H or alkoxy, and R7 is H, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 17, 2015
    Date of Patent: August 21, 2018
    Assignee: ORX PHARMACEUTICAL CORPORATION
    Inventor: Alexander MacGregor
  • Patent number: 10052302
    Abstract: The green synthesis of a reduced graphene oxide (rGO) silica (SiO2) nanocomposite using Nigella sativa seed extract includes mixing a quantity of carbon source in an acid solution while stirring to obtain a solution; adding a first oxidant gradually into the solution to oxidize the soot and obtain a first suspension; stirring the first suspension while maintaining a temperature of the suspension to about 35° C.; adding plant seeds extract to the first suspension while raising the temperature of the suspension to about 60° C.; adding a second oxidant to the suspension to form the reduced graphene oxide nanoparticles; isolating the reduced graphene oxide nanoparticles by centrifugation; suspending the reduced graphene oxide nanoparticles in water; adding a solution comprising tetraethyl orthosilicate (TEOS), concentrated aqueous ammonia solution and a plant seeds extract under ultrasonication; and increasing the temperature to about 90° C. to form reduced graphene oxide-silicon dioxide nanocomposite suspension.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 21, 2018
    Assignee: KING SAUD UNIVERSITY
    Inventors: Manal Ahmed Gasmelseed Awad, Awatif Ahmed Hendi, Khalid Mustafa Osman Ortashi, Amel Laref
  • Patent number: 10052303
    Abstract: The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: August 21, 2018
    Assignee: TEEWINOT TECHNOLOGIES LIMITED
    Inventor: Robert Winnicki
  • Patent number: 10052304
    Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form H2O2, and one or more anti-cancer therapies.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: August 21, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Bryan G. Allen, Douglas R. Spitz, Garry R. Buettner, Joseph Cullen, Joshua Schoenfeld, Michael Schultz, Fenghuang Zhan
  • Patent number: 10052305
    Abstract: In various embodiments methods and composition are provided for the treatment and/or prophylaxis of cystinuria. In certain embodiments the methods involve administering to a mammal in need thereof (e.g., identified as at risk for, or having cystinuria) an effective amount of lipoic acid and/or one or more lipoic acid derivatives.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 21, 2018
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Tiffany Zee, Marshall L. Stoller, Pankaj Kapahi
  • Patent number: 10052306
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 21, 2018
    Assignee: CADENT THERAPEUTICS, INC.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Patent number: 10052307
    Abstract: The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 21, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Motoichi Kurisawa, Yongvongsoontorn Nunnarpas, Jackie Y Ying, Joo Eun Chung, Ki Hyun Bae, Min-han Tan, Esther Lee
  • Patent number: 10052308
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 21, 2018
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 10052309
    Abstract: The present disclosure provides compositions including a bis-cyclic guanidine compound, pharmaceutical compositions including a bis-cyclic guanidine compound, methods of treatment of a condition (e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 21, 2018
    Assignees: University of South Florida, Torrey Pines Institute for Molecular Studies
    Inventors: Lindsey Neil Shaw, Renee Marie Fleeman, Richard Allen Houghten, Marcello Angelo Giulianotti, Radleigh G. Santos, Adel Nefzi
  • Patent number: 10052310
    Abstract: In some embodiments, the present disclosure pertains to compositions with compounds that inhibit Separase activity. In additional embodiments, the present disclosure pertains to methods of treating a tumor in a subject by administering one or more compositions of the present disclosure to the subject.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: August 21, 2018
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Debananda Pati, Nenggang Zhang
  • Patent number: 10052311
    Abstract: The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 21, 2018
    Assignee: INVENTIVA
    Inventors: Irena Konstantinova, Jean-Michel Luccarini, Jean-Louis Junien, Pierre Broqua
  • Patent number: 10052312
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 21, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Markus Follmann, Ingo Hartung, Philipp Buchgraber, Rolf Jautelat, Jorma Haβfeld, Niels Lindner, Alexey Gromov, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Andreas Knorr
  • Patent number: 10052313
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 21, 2018
    Assignee: PRESBYOPIA THERAPIES, LLC
    Inventors: Gerald Horn, Lee Nordan
  • Patent number: 10052314
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: August 21, 2018
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Isan Chen
  • Patent number: 10052315
    Abstract: Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6 -dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 21, 2018
    Assignee: Celgene Corporation
    Inventors: Ho-Wah Hui, Yu Pu
  • Patent number: 10052316
    Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: August 21, 2018
    Assignee: Cardero Therapeutics, Inc.
    Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
  • Patent number: 10052317
    Abstract: The invention provides a neurokinin 3 receptor (NKR3) antagonist for use in the treatment, prevention or amelioration of hot flushes in a human subject, for example a menopausal woman or a patient undergoing cancer therapy which affects secretion of sex steroids. The invention also provides a NKR3 antagonist together with a further active agent, and a composition and a kit comprising a NKR3 antagonist and a further active agent. The invention further provides a NKR3 agonist or exogenous NKB for the induction of hot flushes in a human subject.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 21, 2018
    Assignee: Imperial Innovations Limited
    Inventors: Waljit Dhillo, Channa Jayasena
  • Patent number: 10052318
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 21, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Patent number: 10052319
    Abstract: The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 21, 2018
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventor: Tsuyoshi Tsujimura
  • Patent number: 10052320
    Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: August 21, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Steven John Woodhead, Christopher William Murray, Valerio Berdini, Gordon Saxty, Gilbert Ebai Besong, Lieven Meerpoel, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet